Assessing Organon (OGN) Valuation After A Sharp Share Price Rally

Simply Wall St.

Apr 28

AdvertisementWhy Organon Is Back On Investors’ Radar Organon (OGN) has caught more attention recently as the share price moved sharply over the past month, with returns also positive over the past 3 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2630321971"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630321971\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630321971?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","is_english":true,"pubTime":"2026-04-28 13:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630321971","market":"sg","top_or_hot":-1,"title":"Assessing Organon (OGN) Valuation After A Sharp Share Price Rally","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Organon Is Back On Investors’ Radar Organon (OGN) has caught more attention recently as the share price moved sharply over the past month, with returns also positive over the past 3 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/assessing-organon-ogn-valuation-after-a-sharp-share-price-ra\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Organon (OGN) Valuation After A Sharp Share Price Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Organon (OGN) Valuation After A Sharp Share Price Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-28 13:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/assessing-organon-ogn-valuation-after-a-sharp-share-price-ra><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Organon Is Back On Investors’ Radar Organon (OGN) has caught more attention recently as the share price moved sharply over the past month, with returns also positive over the past 3 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/assessing-organon-ogn-valuation-after-a-sharp-share-price-ra\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OGN","symbol_name":"Organon & Co","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/assessing-organon-ogn-valuation-after-a-sharp-share-price-ra","article_id":"2630321971","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ogn/organon/news/assessing-organon-ogn-valuation-after-a-sharp-share-price-ra","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630321971","pubTimestamp":1777352977,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Organon Is Back On Investors’ Radar\nOrganon (OGN) has caught more attention recently as the share price moved sharply over the past month, with returns also positive over the past 3 months and year to date.\nSee our latest analysis for Organon.\nThe latest move to a US$13.16 share price caps a sharp run, with a 30 day share price return of 125.34% and year to date share price return of 81.77%. However, the 3 year total shareholder return of 38.29% indicates that momentum is relatively...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"OGN":"Organon & Co","BK4559":"巴菲特持仓","BK4007":"制药","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC"},"translate_title":"股价大幅上涨后评估Organon(OGN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGN":1.5,"DCF":1},"content_text":"AdvertisementWhy Organon Is Back On Investors’ Radar Organon (OGN) has caught more attention recently as the share price moved sharply over the past month, with returns also positive over the past 3 months and year to date. See our latest analysis for Organon. The latest move to a US$13.16 share price caps a sharp run, with a 30 day share price return of 125.34% and year to date share price return of 81.77%. However, the 3 year total shareholder return of 38.29% indicates that momentum is relatively recent. If Organon’s swing has you rethinking where opportunities might be building, this could be a good time to scan other healthcare names using our screen for 32 healthcare AI stocks With the share price now above the average analyst target and an implied 83.52% intrinsic discount, investors are left with a key question: is Organon still undervalued or is the market already pricing in future growth? Most Popular Narrative: 46.2% Overvalued Compared with the last close at $13.16, the most followed narrative points to a fair value of $9.00, suggesting the market price sits well above that anchor.  The company's continued debt reduction and strong free cash flow generation enhance financial flexibility, enabling further pipeline investments and M&A opportunities, both of which can accelerate long-term earnings growth and mitigate risks from patent cliffs or single-segment concentration.  Read the complete narrative. Curious what justifies a lower fair value despite upbeat expectations for earnings growth, margin gains and pipeline contributions? The full narrative ties those moving parts into one tight valuation story. Result: Fair Value of $9.00 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upbeat story can unravel if Organon’s heavy reliance on mature, off-patent products and ongoing restructuring costs puts more pressure on revenue and margins. Find out about the key risks to this Organon narrative. Another Take: Big Gap Between DCF And Market Price The first narrative points to a fair value of $9.00 and labels Organon as overvalued at $13.16. Yet the Simply Wall St DCF model estimates future cash flows at $79.86 per share, which is very far above the current price and implies a very different risk reward profile. For anyone weighing these two signals, it helps to understand exactly how that cash flow model works and what would need to hold true for such a wide gap to close over time, or fail to close at all. Look into how the SWS DCF model arrives at its fair value. OGN Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Organon for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps The mix of optimism and caution in this article reflects how divided the case for Organon really is. Consider reviewing the data for yourself and weighing both sides using our 2 key rewards and 4 important warning signs. Ready To Hunt For Your Next Idea? If Organon has you thinking more broadly about opportunities, do not stop here. Use the screeners below now so you are not catching up later.  Spot potential mispricings by scanning companies that combine quality with value using our 53 high quality undervalued stocks. Secure more reliable cash flow potential by focusing on companies highlighted in the 13 dividend fortresses. Prioritize resilience by zeroing in on companies with strong financial footing through the solid balance sheet and fundamentals stocks screener (43 results).   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}